TEMPO SC ULTRA INSECTICIDE
002 07/21/99 TEMPO SC ULTRA INSECTICIDE
****************************************************************************
PRODUCT IDENTIFICATION
****************************************************************************
PRODUCT NAME: TEMPO SC ULTRA INSECTICIDE
MSDS#: P22228VS
DATE ISSUED: 12/8/98
SUPERSEDES: 5/21/98
ISSUED BY: 009771
TRANSPORTATION EMERGENCY NON-TRANSPORTATION
CALL CHEMTREC: 800-424-9300 vendor EMERGENCY PHONE : (800) 414-0244
1. CHEMICAL PRODUCT IDENTIFICATION:
PRODUCT NAME : TEMPO SC Ultra Insecticide
CHEMICAL FAMILY : Pyrethroid Insecticide
CHEMICAL NAME : Cyano(4-fluoro-3-phenoxyphenyl)methyl 3-(2,2
-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
SYNONYMS : beta-cyfluthrin
FORMULA : C22 H18 C12 F N O3
2. COMPOSITION/INFORMATION ON INGREDIENTS:
INGREDIENT NAME
/CAS NUMBER EXPOSURE LIMITS CONCENTRATION (%)
HAZARDOUS INGREDIENTS
FOR 4545 Technical (beta-cyfluthrin)
68359-37-5 OSHA : Not Established 11.8 %
ACGIH: Not Established
Specific chemical identity is withheld as a trade secret.
OSHA : Not Established 1-3 %
ACGIH: Not Established
3. HAZARDS IDENTIFICATION:
EMERGENCY OVERVIEW
CAUTION! Color: Beige; Form: Liquid; Off-white to beige
viscous liquid suspension; Odor: Chalky; Harmful if
inhaled; Harmful if absorbed through skin; Causes eye
irritation.
POTENTIAL HEALTH EFFECTS:
ROUTE(S) OF ENTRY : Inhalation; Skin Contact; Skin Absorption;
Eye Contact
HUMAN EFFECTS AND SYMPTOMS OF OVEREXPOSURE:
ACUTE EFFECTS OF EXPOSURE : Skin and mucous membrane irritation may occur
from contact with the product and produce symptoms such as itching,
stinging, skin reddening or rash. Paresthesia (a tingling or burning
sensation on the surface of the skin) may also result from skin contact.
These are frequently reported symptoms associated with sufficient dermal
exposure to alpha-cyano (Type II) synthetic pyrethroids and normally
subside without treatment within 24 hours. The onset of these symptoms
usually occurs 2-12 hours after exposure. The effects are temporary and
are reversible. Based on the EPA Toxicity Category criteria, this material
is mildly toxic by the oral and dermal routes of exposure. In addition,
animal studies have shown that it can cause mild irritation to the
conjunctive of the eye with all irritation resolving within 7 days.
CHRONIC EFFECTS OF EXPOSURE...: Based on animal studies, no adverse effects or
symptoms would be expected from chronic exposure to this material.
CARCINOGENICITY : This product is not listed by NTP, IARC or
regulated as a carcinogen by OSHA.
MEDICAL CONDITIONS
AGGRAVATED BY EXPOSURE : No specific medical conditions are known which
may be aggravated by exposure to this product. As with all materials which
can cause upper respiratory tract irritation, persons with a history of
asthma, emphysema, or hyperreactive airways disease may be more susceptible
to overexposure.
4. FIRST AID MEASURES:
FIRST AID FOR EYES : Hold eyelids open and flush with copious amounts of
water for 15 minutes. Call a physician if irritation develops or persists
after flushing.
FIRST AID FOR SKIN : Remove contaminated clothing immediately. Wash skin
with soap and water, preferably preceded by a waterless hand cleaner. Get
medical attention if irritation develops or persists. If signs of
intoxication (poisoning) occur, get medical attention immediately.
FIRST AID FOR INHALATION: If a person is overcome by excessive exposures to
aerosols or vapors of this material, remove to fresh air or uncontaminated
area. If not breathing, give artificial respiration, preferably
mouth-to-mouth. Get medical attention as soon as possible.
FIRST AID FOR INGESTION: If ingestion is suspected, call a physician or poison
control center. Drink one or two glasses of water and induce vomiting by
touching back of throat with finger, or, if available, by administering
syrup of ipecac. If syrup of ipecac is available, administer 1
tablespoonful (15 mL) of syrup of ipecac followed by 1 to 2 glasses of
water. If vomiting does not occur within 20 minutes, repeat the dose once.
Do not induce vomiting or give anything by mouth to an unconscious person.
NOTE TO PHYSICIAN : ANTIDOTE: No specific antidote is available. Treat
victim symptomatically. Published data indicate vitamin E acetate can
prevent and/or mitigate symptoms of paresthesia caused by synthetic
pyrethroids. In case of poisoning, it is also requested that vendor ,
Agriculture Division, Kansas City, Missouri, be notified. Telephone:
1-800-414-0244
5. FIRE FIGHTING MEASURES:
FLASH POINT : Greater than 200 F (93 C)
EXTINGUISHING MEDIA : Water; Foam; Dry Chemical
SPECIAL FIRE FIGHTING PROCEDURES: Keep out of smoke. Cool exposed containers
with water spray. Fight fire from upwind position. Use self-contained
breathing equipment. Contain runoff to prevent entry into sewers or
waterways. Equipment or materials involved in pesticide fires may become
contaminated.
6. ACCIDENTAL RELEASE MEASURES:
SPILL OR LEAK PROCEDURES : Isolate area and keep unauthorized people
away. Do not walk through spilled material. Avoid breathing vapors and
skin contact. Remove sources of ignition if combustible or flammable
vapors may be present and ventilate area. Wear proper protective
equipment. Dike contaminated area with absorbent granules, soil, sand,
etc. If large spill, material should be recovered. Small spills can be
absorbed with absorbent granules, spill control pads, or any absorbent
material. Carefully sweep up absorbed spilled material. Place in covered
container for reuse or disposal. Scrub contaminated area with soap and
water. Use dry absorbent materials such as clay granules to absorb and
collect wash solution for proper disposal. Contaminated soil may have to
be removed and disposed. Do not allow material to enter streams, sewers,
or other waterways or contact vegetation.
7. HANDLING AND STORAGE:
STORAGE TEMPERATURE(MIN/MAX): 0 F/30 day avg. not to exceed 100 F
SHELF LIFE : Time/temperature-dependent. Contact vendor for
specific information.
SPECIAL SENSITIVITY : Not established
HANDLING/STORAGE PRECAUTIONS:Store in a cool, dry area designated specifically
for pesticides.
8. PERSONAL PROTECTION:
EYE PROTECTION REQUIREMENTS : Goggles should be used to prevent liquid
from getting into eyes.
SKIN PROTECTION REQUIREMENTS : Avoid skin contact. Wear long sleeves and
trousers.
HAND PROTECTION REQUIREMENTS : Chemical-resistant gloves such as neoprene
VENTILATION REQUIREMENTS : Control exposure levels through the use of
general and local exhaust ventilation.
RESPIRATOR REQUIREMENTS : When respiratory protection is necessary
under the conditions of use, wear a NIOSH-approved organic vapor
respirator with dust and mist filter.
ADDITIONAL PROTECTIVE MEASURES : Clean water and soap should be available
for washing in case of eye or skin contamination. Waterless hand cleaner
use is often more effective than soap and water. Sensitive areas of the
skin and mucous membranes can become contaminated indirectly. Educate and
train employees in safe use of the product. Follow all label instructions.
Launder clothing separately after use. Wash thoroughly after handling.
9. PHYSICAL AND CHEMICAL PROPERTIES:
PHYSICAL FORM : Liquid
APPEARANCE : Off-white to beige viscous liquid suspension
COLOR : Beige
ODOR : Chalky
MOLECULAR WEIGHT : 434.3 (for beta-cyfluthrin)
pH : 7-8
BOILING POINT : Not established
MELTING/FREEZING POINT : Approx. 20 F
VISCOSITY : 1060 cps @ 23 C
SOLUBILITY IN WATER : Not established
SPECIFIC GRAVITY : 1.06 @ 20 C/20 C
BULK DENSITY : Not established
VAPOR PRESSURE : 7.2 x 10-9 mm Hg @ 20 C (for beta-cyfluthrin)
10. STABILITY AND REACTIVITY:
STABILITY : This is a stable material.
HAZARDOUS POLYMERIZATION: Will not occur.
INCOMPATIBILITIES : Alkaline media; reacts with methanol; incompatible
with many disinfectants.
INSTABILITY CONDITIONS : Not established
DECOMPOSITION PRODUCTS : Not established
11. TOXICOLOGICAL INFORMATION:
Only acute studies have been performed on this product as formulated. The
non-acute information pertains to the active ingredient, cyfluthrin technical,
and its enriched isomer mixture, BAY FCR 4545 technical.
ACUTE TOXICITY
ORAL LD50 : Male rat: 960 mg/kg -- Female rat: 1150 mg/kg
DERMAL LD50 : Male and Female Rat: >2000 mg/kg
INHALATION LC50 : 4 hr exposure to Liquid Aerosol: Male and Female Rat:
>1.72 mg/L (analytical) -- 1 hr exposure to Liquid Aerosol (extrapolated
from 4 hr): Male and Female Rat: >6.88 mg/L (analytical)
EYE EFFECTS : Rabbit: Mild irritation to the conjunctive was
observed with all irritation cleared within 7 days post-treatment.
SKIN EFFECTS : Rabbit: Not a dermal irritant
SENSITIZATION : Guinea pig: Not a dermal sensitizer
SUBCHRONIC TOXICITY : FCR 4545: In a 13 week dog study, FCR 4545 was
administered at dietary concentrations of 10, 60 or 360 ppm. Effects included
vomiting and diarrhea after feeding, decreased body weight gain, and motor
disturbances in the hind limbs. The no-observed effect-level (NOEL) was 60
ppm. In a 13 week study using rats, FCR 4545 was administered at dietary
concentrations of 30, 125 or 500 ppm. Effects included reduced body weight
gains and feed consumption, uncoordinated gait, and skin injuries of the neck
and head from excessive preening due to the local irritant effect of the test
material. The NOEL was 125 ppm. In a 4 week inhalation study, rats were
exposed to FCR 4545 at liquid aerosol concentrations of 0.2, 2.7 or 23.5
mg/m3. Effects observed included ungroomed hr, piloerection, hyper- and
hypoactivity, reduced body weight gains, reduced organ weights (thyeus and
spleen), and hematological changes. The NOEL was 0.2 mg/m3 based on decreased
body weight gains. CYFLUTHRIN: In a 3 week dermal toxicity study, cyfluthrin
was administered to rats for 6 hours/day at dose levels of 100, 340 or 1000
mg/kg. Animals received a total of 17-18 applications in a period of 22-23
days. An additional control and high-dose group were treated and maintained
for 14-15 days following treatment so as to ascertain the extent of recovery.
Effects observed included reduced feed consumption, red nasal discharge, urine
stains, and findings at the dose site (scabbing, crusty, discolored and raised
zones). histologically, epidermal and dermal alterations in treated skin were
observed in animals of the mid- and high-dose groups. Similar, but slightly
less severe microscopic alterations were also observed in the high-dose
recovery group. The overall NOEL was 100 mg/kg. In a 13 week inhalation
study, rats were exposed to cyfluthrin at aerosol concentrations of 0.09, 0.71
or 4.51 mg/m3 for 6 hours/day, 5 days/week. The NOEL was 0.09 mg/m3 based on
reduced body weight gains.
CHRONIC TOXICITY : Cyfluthrin has been investigated in chronic feeding
studies using two different strains of rats. In each study, cyfluthrin was
administered for 2 years at dietary concentrations ranging from 50 to 450 ppm.
Body weight gains were decreased at concentrations of 150 ppm and greater.
Changes in clinical chemistries occurred at 450 ppm. In one of the studies,
histopathology revealed a numerical increase in mammary gland adenocarcinomas
at 450 ppm. This finding was not statistically significant when compared to
the controls and is not considered to be compound-related. In each study, the
overall NOEL was 50 ppm based on decreased body weight gains. In a 1 year
feeding study, dogs were administered cyfluthrin at dietary concentrations of
50, 100, 360 or 650 ppm. Beginning on week 8, the high dose was reduced to
500 ppm for the remainder of the study due to severe clinical neurological
symptoms. Body weights were decreased for animals of the high-dose.
Neurological findings (gait abnormalities and postural reaction deficits) were
observed at doses of 360 and greater. The NOEL was 100 ppm.
CARCINOGENICITY : Cyfluthrin was investigated for carcinogenicity in
chronic studies using rats and mice at maximum levels of 450 and 800 ppm,
respectively. There was no evidence of a carcinogenic potential observed in
either species.
MUTAGENICITY : In vitro and in vivo mutagenicity studies have been
conducted on BAY FCR 4545 technical, all of which are negative. Numerous in
vitro and in vivo mutagenicity studies have been conducted on cyfluthrin, all
of which are negative.
DEVELOPMENTAL TOXICITY: FCR 4545: In a developmental toxicity study, Bay FCR
4545 technical was administered orally to rats during gestation at doses of 3,
10 or 40 mg/kg. At the lethal and maternally toxic dose of 40 mg/kg, there
was a decrease in fetal body weights and an increased incidence of skeletal
findings. The NOELs for maternal and developmental toxicity were 3 and 10
mg/kg, respectively. Cyfluthrin: In developmental toxicity studies using
rats, cyfluthrin was administered during gestation by oral Savage at doses
ranging from 1 to 30 mg/kg. The overall NOEL from these studies for maternal
toxicity was 3 mg/kg. No developmental effects were observed at any of the
doses tested. In each study, the NOEL for developmental toxicity was
equivalent to the highest dose tested. The NOELs for developmental toxicity
for the initial study and the subsequent study were 30 and 10 mg/kg,
respectively. Rabbits were administered cyfluthrin during gestation by oral
gavage at doses ranging from 5 to 180 mg/kg. At maternally toxic levels,
there was an increased incidence of post-implantation losses. The overall
NOEL derived from these studies for both maternal and developmental toxicity
was 20 mg/kg. In an inhalation study, rats were exposed during gestation to
cyfluthrin at aerosol concentrations of 0.46, 2.55 or 11.9 mg/m3 for 6
hours/day. NOELs for maternal and developmental toxicity were less than 0.46
and 0.46 mg/m3, respectively.
REPRODUCTION : In a reproduction study, cyfluthrin was administered to
rats for 3 generations at dietary concentrations of 50, 150 and 450 ppm.
Reproductive effects observed at parentally toxic levels included reductions
in viability, lactation, litter size, feed consumption, and pup birth weights
and body weight gains. Coarse tremors were observed in some offspring at 450
ppm. The NOEL for both parental and reproductive effects was 50 ppm. In
another reproduction study, cyfluthrin was administered to rats for 2
generations at dietary concentrations of 50, 125 or 400 ppm. Coarse tremors
occurring in conjunction with parental toxicity were observed in the offspring
in the mid- and high-dose groups. Based on this finding, the neonatal NOEL
was 50 ppm. The NOELs for parental and reproductive toxicity were 50 and 400
ppm, respectively.
NEUROTOXICITY : Numerous neurotoxicity studies have been conducted on
cyfluthrin. Oral gavage studies using hens have indicated that at extremely
high dose levels (5000 mg/kg), minimal nerve damage occurs. When rats were
administered cyfluthrin daily at oral doses of 40 to 80 mg/kg for 14 days,
minimal nerve effects were seen. These effects were completely reversible
within a 3 month recovery period. In dermal and inhalation studies which are
relevant to field exposure, there was no evidence of delayed neurotoxicity in
hens. In a special investigative study, litters of neonatal mice (10 days of
age) and their mothers were exposed to aerosol concentrations of 5, 15, or 50
mg/m3 for 6.3 hours/day for 7 successive days. Motor activity was measured in
the offspring at 4 months of age (approximately 3.5 months post-exposure). At
50 mg/m3, all of the offsprings died or were sacrificed in a moribund state
following the first exposure. Mortalities were not observed at any of the
other levels. Clinical symptoms were observed immediately after exposure in
young mice at 15 mg/m3, and included decreased motility, temporary scratching,
and tonic convulsions. There was an increase in motor activity in mice at 15
mg/m3. histopathological investigations did not reveal any treatment-related
findings in mice at the age of 4 months.
12. ECOLOGICAL INFORMATION:
This product is extremely toxic to fish and aquatic invertebrates, and is
highly toxic to bees. vendor will provide a summary of specific data upon
written request. As with any pesticide, this product should be used according
to label directions and should be kept out of streams, lakes and other aquatic
habitats of concern. In event of a spill emergency, call 1-800-414-0244.
13. DISPOSAL CONSIDERATIONS
WASTE DISPOSAL METHOD : Follow container label instructions for disposal
of wastes generated during use in compliance with the FIFRA product label.
In other situations, bury in an EPA approved landfill or burn in an
incinerator approved for pesticide destruction.
EMPTY CONTAINER PRECAUTIONS: Do not reuse container without written permission
and instructions from vendor. Empty, clean and dispose in accordance with
state and local laws.
14. TRANSPORTATION INFORMATION:
TECHNICAL SHIPPING NAME : beta-Cyfluthrin
FREIGHT CLASS PACKAGE : Insecticides, NOI, NMFC 102100
PRODUCT LABEL : Not Noted
DOT (DOMESTIC SURFACE)
HAZARD CLASS OR DIVISION: Non regulated
It is not expected that a mist or vapor hazard would exist from the normal
transportation of this liquid substance.
IMO / IMDG CODE (OCEAN)
HAZARD CLASS OR DIVISION: Non regulated
ICAO / IATA (AIR)
HAZARD CLASS OR DIVISION: Non regulated
15. REGULATORY INFORMATION:
OSHA STATUS : This product is hazardous under the criteria of
the Federal OSHA Hazard Communication Standard 29
CFR 1910.1200.
TSCA STATUS : This product is exempt from TSCA Regulation under
FIFRA Section 3 (2)(B)(ii) when used as a pesticide.
CERCLA REPORTABLE QUANTITY : No components listed.
SARA TITLE III:
SECTION 302 EXTREMELY HAZARDOUS SUBSTANCES : No components listed.
SECTION 311/312
HAZARD CATEGORIES : Immediate Health Hazard
SECTION 313
TOXIC CHEMICALS : beta-Cyfluthrin (11.8%) - CAS # 68359-37-5
RCRA STATUS : If discarded in its purchased form, this product
would not be a hazardous waste either by listing
or by characteristic. However, under RCRA, it is
the responsibility of the product user to
determine at the time of disposal, whether a
material containing the product or derived from
the product should be classified as a hazardous
waste. (40 CFR 261.20-24)
16. OTHER INFORMATION:
NFPA 704M RATINGS: Health Flammability Reactivity Other
1 1
O=Insignificant 1=Slight 2=Moderate 3=High 4=Extreme
For emergency assistance involving chemicals,
call CHEMTREC - (800)
424-9300
Vopak USA
6100 Carillon Point, Kirkland WA 98033 - (425)
889-3534
Vopak USA expressly disclaims all express or implied warranties of
merchantability and fitness for a particular purpose, with respect to the
product or information provided herein, and shall under no circumstances be
liable for incidental or consequential damages.
All information appearing
herien is based upon data obtained from the manufacturer and/or recognized
technical sources. While the information is believed to be accurate, Vopak USA
makes no representations as to its accuracy or suffiency. Conditions of use are
beyond Vopak USA's control and therefore users are responsible to verify this
data under their own operating conditions to determine whether the product is
suitable for their particular purposes and they assume all risks of their use,
handling, and disposal of the product, or from the publication or use of, or
reliance upon, information contained herein. This information relates only to
the product designated herein, and does not relate to its use in combination
with any other material or in any other process.
We welcome your Feedback!
By
using this Web site, you agree to be bound by our usage policies
to learn
more see Copyright©
1998, Vopak USA